« Back
Home /
Taspoglutide

Taspoglutide

Item no.	HY-P0165-1mg
Manufacturer	MedChem Express
CASRN	275371-94-3
Amount	1 mg
Quantity options	10 mMx1 mL 10 mg 1 mg 25 mg 5 mg
Category	Neuroscience Metabolism Diabetes Cholesterol & Lipid Metabolism Regulation of Appetite Molecular Targets for Neuroscience Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.51
Citations	[1]Sebokova E, et al. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. Endocrinology. 2010 Jun;151(6):2474-82.\|[2]Retterstol K, et al. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert Opin Investig Drugs. 2009 Sep;18(9):1405-11.\|[3]Nauck MA, et al. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care. 2009 Jul;32(7):1237-43.\|[4]Sebokova E, et al. Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat. Diabetes Obes Metab. 2010 Aug;12(8):674-82.\|[5]Panjwani N, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology. 2013 Jan;154(1):127-39.\|[6]Panjwani N, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology. 2013 Jan;154(1):127-39.
Smiles	N=C(N)NCCC[C@@H](C(N)=O)NC(C(C)(C)NC([C@H](CCCCN)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](C)NC([C@H]([C@@H](C)CC)NC([C@@H](NC([C@H](CCC(O)=O)NC([C@H](CCCCN)NC([C@H](C)NC([C@H](C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CO)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(O)=O)NC(C(C)(C)NC([C@@H](N)CC1=CN=CN1)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)CC5=CNC6=CC=CC=C56)=O)=O)=O)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ITM077,R1583,BIM51077
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	GCGR
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Molecular Weight	3339.71
Product Description	Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
Manufacturer - Research Area	Metabolic Disease
Solubility	DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P0165-1mg-safety-datasheet.pdf